Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834801 | 0.99 | PTPN2 (0.47) | PTPN2PTPN1TP53TSHRNAMPT | |
| SCHEMBL25642221 | 0.95 | PTPN2 (0.43) | PTPN2PTPN1TP53TSHRNAMPT | |
| SCHEMBL25642282 | 0.95 | PTPN2 (0.43) | PTPN2PTPN1TP53TSHRNAMPT | |
| SCHEMBL25222285 | 0.95 | PTPN2 (0.43) | PTPN2PTPN1TP53TSHRNAMPT | |
| SCHEMBL25261833 | 0.95 | PTPN2 (0.43) | PTPN2PTPN1TP53TSHRNAMPT | |
| SCHEMBL19834806 | 0.91 | NAMPT (0.46) | PTPN2PTPN1NAMPTALDH1A1POLB | |
| SCHEMBL19834815 | 0.90 | PTPN2 (0.43) | PTPN2PTPN1NAMPTALDH1A1POLB | |
| SCHEMBL27111075 | 0.87 | NAMPT (0.35) | PTPN2PTPN1NAMPTKMT2A | |
| SCHEMBL27111089 | 0.87 | NAMPT (0.35) | PTPN2PTPN1NAMPTKMT2A | |
| SCHEMBL19834835 | 0.87 | PTPN2 (0.48) | PTPN2PTPN1TP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | claimed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | claimed |
| EP-3279192-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2018-02-07 | — | — | EP | claimed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| WO-2018024907-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2018-02-08 | — | — | WO | disclosed |
| EP-3279192-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279192-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | RNASE1, PKD1, GPR6 | PTPN2 1725/4885PTPN1 841/4885TP53 904/4885 |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | RNASE1, PKD1, GPR6 | PTPN2 1594/4885PTPN1 759/4885TP53 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.